 Connection
Benjamin Bitler to Cell Line, Tumor
This is a "connection" page, showing publications Benjamin Bitler has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.413 |
|
|
|
-
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG. SM08502-Mediated ß-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. Cancer Res Commun. 2025 12 01; 5(12):2112-2126.
Score: 0.130
-
Bitler BG, Lang J, Nunez-Avellaneda D, Behbakht K, Davidson NR, Woodruff ER, Villagomez FR. Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer. Sci Rep. 2025 Nov 10; 15(1):39257.
Score: 0.130
-
Villagomez FR, Lang J, Nunez-Avellaneda D, Behbakht K, Dimmick HL, Webb PG, Nephew KP, Neville M, Woodruff ER, Bitler BG. Claudin-4 Stabilizes the Genome via Nuclear and Cell-Cycle Remodeling to Support Ovarian Cancer Cell Survival. Cancer Res Commun. 2025 01 01; 5(1):39-53.
Score: 0.122
-
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner. Mol Cancer Res. 2024 12 03; 22(12):1117-1127.
Score: 0.122
-
Villagomez FR, Lang J, Rosario FJ, Nunez-Avellaneda D, Webb P, Neville M, Woodruff ER, Bitler BG. Claudin-4 Modulates Autophagy via SLC1A5/LAT1 as a Mechanism to Regulate Micronuclei. Cancer Res Commun. 2024 07 01; 4(7):1625-1642.
Score: 0.118
-
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Cocozaki A, Chuong EB, Bitler BG. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. Mol Cancer Ther. 2024 09 01; 23(9):1332?1347.
Score: 0.117
-
Persenaire C, Babbs B, Yamamoto TM, Nebbia M, Jordan KR, Adams S, Lambert JR, Bitler BG. VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression. Mol Carcinog. 2024 07; 63(7):1248-1259.
Score: 0.116
-
Bapat J, Yamamoto TM, Woodruff ER, Qamar L, Mikeska RG, Aird KM, Watson ZL, Brubaker LW, Bitler BG. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR. Cancer Gene Ther. 2024 02; 31(2):300-310.
Score: 0.113
-
Bitler BG, Bailey CA, Yamamoto TM, McMellen A, Kim H, Watson ZL. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma. Mol Carcinog. 2023 11; 62(11):1717-1730.
Score: 0.111
-
McMellen A, Yamamoto TM, Qamar L, Sanders BE, Nguyen LL, Ortiz Chavez D, Bapat J, Berning A, Post MD, Johnson J, Behbakht K, Nurmemmedov E, Chuong EB, Bitler BG. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Mol Cancer Res. 2023 01 03; 21(1):3-13.
Score: 0.106
-
Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020 07; 18(7):1088-1098.
Score: 0.088
-
Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 11 27; 11(1):165.
Score: 0.086
-
Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. Mol Cancer Ther. 2020 02; 19(2):602-613.
Score: 0.085
-
Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019 10; 58(10):1770-1782.
Score: 0.083
-
Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ, Zou W, Speicher DW, Huntsman DG, Conejo-Garcia JR, Cho KR, Christianson DW, Zhang R. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol. 2017 08; 19(8):962-973.
Score: 0.073
-
Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM, Conejo-Garcia JR, Speicher DW, Zhang R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015 Mar; 21(3):231-8.
Score: 0.062
-
Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, Li T, Birrer MJ, Godwin AK, Cairns P, Zhang R. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 2011 Oct 01; 71(19):6184-94.
Score: 0.048
-
Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci. 2010 May 15; 123(Pt 10):1716-23.
Score: 0.044
-
Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, Schroeder JA. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res. 2009 Jan 01; 15(1):100-9.
Score: 0.040
-
Cheng K, Nie H, Zhou W, Guo D, Liao L, Zhang X, Wang C, Zielinski RJ, Gavade JN, Sriramkumar S, Fang Y, Xia S, Wu S, Tang HY, Kossenkov AV, Qi Y, Liu J, Le K, Gruber D, Soth MJ, Post MD, Sood AK, Flückiger-Mangual S, Yap TA, Bitler BG, Zhang R. Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. Cancer Res. 2026 Oct 02; 86(19):4934-4954.
Score: 0.035
-
Mikeska RG, Feldman LER, Woodruff ER, Iwanaga R, Linder KE, Yamamoto TM, Sompel K, Jordan KR, Post MD, Zoller M, Bitler BG, Marjon NA. Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma. Cancer Res Commun. 2026 Sep 01; 6(9):2256-2270.
Score: 0.034
-
Cole AR, Buj R, Uboveja A, Levasseur E, Tom A, Wang H, Kedziora KM, Chatoff A, Huacachino AA, Marcinkiewicz MM, Amalric A, Yang B, Tangudu NK, Noonan E, Danielson J, Naruse M, Elhaw AT, White S, Li D, Wallace CT, Keeney F, Lazure F, Elishaev E, Borho L, Townsend HA, Dowell RD, Clauset A, Jazwinska DE, Laird MS, Atiya H, Dangaj D, Coffman LG, Tseng G, Oesterreich S, Kossenkov A, Liu Q, Gomes AP, Gurkar AU, Schopfer FJ, Modugno F, Watkins SC, Zervantonakis IK, Bitler BG, Stallaert W, Hempel N, Snyder NW, Aird KM. The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming. Nat Aging. 2026 Aug; 6(8):1647-1666.
Score: 0.034
-
Yamamoto TM, Iwanaga R, Woodruff ER, Elder AM, Petkov A, Nurmemmedov E, Eisenmesser E, Reigan P, Bitler BG, Brubaker LW. Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. Mol Cancer Ther. 2026 Jul 02; 25(7):1130-1143.
Score: 0.034
-
Shao C, Indeglia A, Foster M, Casey K, Leung J, Modarai SR, Leu JI, Duong B, Mes-Masson AM, Sims-Mourtada J, Auslander N, Drapkin R, Bitler BG, Zhang N, Murphy ME. Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. Genes Dev. 2026 02 02; 40(3-4):199-214.
Score: 0.033
-
Escoto A, Hecksel R, Parkinson C, Crane S, Atwell B, King S, Ortiz Chavez D, Jannuzi A, Sands B, Bitler BG, Fehniger TA, Paek AL, Padi M, Schroeder J. Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity. Oncogene. 2025 02; 44(5):288-295.
Score: 0.030
-
Kuo LW, Crump LS, O'Neill K, Williams MM, Christenson JL, Spoelstra NS, Roy MK, Argabright A, Reisz JA, D'Alessandro A, Boorgula MP, Goodspeed A, Bickerdike M, Bitler BG, Richer JK. Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity. Cancer Res Commun. 2024 10 01; 4(10):2699-2713.
Score: 0.030
-
Iwanaga R, Yamamoto TM, Gomez K, Nguyen LL, Woodruff ER, Post MD, Mikeska RG, Danis E, Danhorn T, Boorgula MP, Mitra SS, Marjon NA, Bitler BG, Brubaker LW. Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. Cancer Res Commun. 2024 08 01; 4(8):1919-1932.
Score: 0.030
-
Ivancevic A, Simpson DM, Joyner OM, Bagby SM, Nguyen LL, Bitler BG, Pitts TM, Chuong EB. Endogenous retroviruses mediate transcriptional rewiring in response to oncogenic signaling in colorectal cancer. Sci Adv. 2024 07 19; 10(29):eado1218.
Score: 0.030
-
Holmberg R, Robinson M, Gilbert SF, Lujano-Olazaba O, Waters JA, Kogan E, Velasquez CLR, Stevenson D, Cruz LS, Alexander LJ, Lara J, Mu EM, Camillo JR, Bitler BG, Huxford T, House CD. TWEAK-Fn14-RelB Signaling Cascade Promotes Stem Cell-like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse. Mol Cancer Res. 2023 02 01; 21(2):170-186.
Score: 0.027
-
Lin J, Guo D, Liu H, Zhou W, Wang C, Müller I, Kossenkov AV, Drapkin R, Bitler BG, Helin K, Zhang R. The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. Cancer Immunol Res. 2021 12; 9(12):1413-1424.
Score: 0.025
-
Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Mol Carcinog. 2021 08; 60(8):511-523.
Score: 0.024
-
Li J, Wang W, Zhang Y, Cieslik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, Wei S, Zhou J, Li G, Jing X, Vatan L, Zhao L, Bitler B, Zhang R, Cho KR, Dou Y, Kryczek I, Chan TA, Huntsman D, Chinnaiyan AM, Zou W. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest. 2020 05 01; 130(5):2712-2726.
Score: 0.022
-
Rao DM, Shackleford MT, Bordeaux EK, Sottnik JL, Ferguson RL, Yamamoto TM, Wellberg EA, Bitler BG, Sikora MJ. Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine O-acyltransferase or Wnt secretion. J Biol Chem. 2019 12 27; 294(52):19950-19966.
Score: 0.021
-
Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, Powell T, Jansson T, Wilson H. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019 Nov; 461(1-2):37-46.
Score: 0.021
-
Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK. Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel. Mol Cancer Res. 2019 03; 17(3):741-750.
Score: 0.020
-
Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 2019 02; 58(2):196-205.
Score: 0.020
-
Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun. 2018 10 08; 9(1):4116.
Score: 0.020
-
Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun. 2018 02 12; 9(1):631.
Score: 0.019
-
Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Rep. 2017 Dec 19; 21(12):3398-3405.
Score: 0.019
-
Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res. 2016 11 01; 76(21):6320-6330.
Score: 0.017
-
Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. Mol Cell Proteomics. 2016 11; 15(11):3348-3360.
Score: 0.017
-
Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, Zhang R. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Rep. 2016 09 13; 16(11):2829-2837.
Score: 0.017
-
Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S, Zhang R. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Mol Cancer Res. 2013 Apr; 11(4):360-9.
Score: 0.013
-
Horm TM, Bitler BG, Broka DM, Louderbough JM, Schroeder JA. MUC1 drives c-Met-dependent migration and scattering. Mol Cancer Res. 2012 Dec; 10(12):1544-54.
Score: 0.013
-
Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang R. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila). 2012 Mar; 5(3):484-91.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|